major depressive disorder therapies

Fabre-Kramer Pharmaceuticals’ major depressive disorder drug, gepirone, faced FDA rejection not once, not twice, but three times since the beginning of the 21st century. Finally, the company can rejoice as the FDA has granted long-awaited approval. On 29 September 2023, the FDA approved Fabre-Kramer Pharmaceuticals...

In the contemporary world, major depressive disorder (MDD) is one of the diseases responsible for the greatest healthcare burden. In the United States, more than 24 million people suffer from major depressive disorder each year, while in Europe, about 20 million are diagnosed with the major depressive disorder each...